Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
pharma · Nonalcoholic Steatohepatitis (NASH) · Amyotrophic Lateral Sclerosis · CORT
CORCEPT THERAPEUTICS
CORCEPT THERAPEUTICS INC
CORCEPT THERAPEUTICS drug portfolio — 36 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
101 Redwood Shores Pkwy, Redwood City, California 94065, US HQ
1998 Founded
756 Employees
Public company Type
CORT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 101 Redwood Shores Pkwy, Redwood City, California 94065, US
- Founded
- 1998
- Employees
- 756
- Programs
- 67
- Drugs
- 36
- Patents
- 120
CORCEPT THERAPEUTICS pipeline
Portfolio lens on 36 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CORCEPT THERAPEUTICS drug portfolio — 36 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dabigatran etexilate
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in CORCEPT THERAPEUTICS's portfolio. Mechanism: Thrombin inhibitor.
- Mechanism
- Thrombin inhibitor
-
US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in CORCEPT THERAPEUTICS's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in CORCEPT THERAPEUTICS's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
mifepristone
Nervous system (NOT)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Progesterone receptor antagonist
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
olanzapine
Nervous system (N05)US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor antagonist
-
risperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.
-
Development asset linked to CORCEPT THERAPEUTICS in public FDA and regional records.